Optimizing the Stupp protocol for treatment of glioblastoma: eliminating age bias, enhancing treatment timing, use of stereotactically-guided sequential boost, and dexamethasone dosing

1

The Stupp protocol for glioblastoma treatment shows inconsistent implementation, particularly in therapeutic timing and radiotherapy modalities.
2

Patients aged ≥ 70 years are often excluded from the Stupp protocol, leading to disparities in treatment and outcomes.
3

Dexamethasone is used to manage edema but may have immunosuppressive effects that could worsen patient outcomes.
4

In a cohort of 269 glioblastoma patients, only 44% aged ≥ 70 years received the standard chemoradiotherapy regimen.
5

The study aims to address critical questions regarding treatment timing, SGS-Boost efficacy, dexamethasone impact, and adjuvant temozolomide cycles.

Journal Of Neuro-Oncology

by Martyn A. Sharpe, Alexandra M. Baskin, Bin S. Teh, E. Brian Butler, David Stuart Baskin
July 3, 2026

1